Report Overview

The Kenya sickle cell drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

The Kenyan market for sickle cell disease treatment has been expanding alongside growing need for treating diseases related to blood plasma. Sickle cell disease (SCD) is the most common hemoglobinopathy encountered in Kenya. In the western part of the country, about 4.5% of children are born with SCD, and 18% of children are born with sickle cell trait. It is estimated that approximately 1,000 children in Africa are born with SCD every day and more than half die before they reach five years of age. Hence, swift treatment procedures for patients with SCD is needed. This factor is projected to accelerate the growth of the Kenya sickle cell disease treatment market in the years to come. The sickle cell disease treatment market is anticipated to attract investments from new avenues over the forthcoming years.



Market Drivers

Sickle cell disease market is driven by the increasing prevalence of sickle cell disease in low- and middle-income countries like Kenya. In addition, increasing product pipeline for treating sickle cell anaemia is expected to create high demand for these treatment options. Sickle cell anaemia treatment market is driven by increasing governments and regulatory bodies support by means of research and development investment, fast track approval for discovering newer treatments for this disorder.

More than 25000 children were screened for SCD between 2012-2019 using isoelectric focusing, and of those found to have SCD, approximately 75% started treatment. At the same time, 1559 clinicians and other health care providers have been trained on how to manage SCD. County authorities have worked together with advocacy groups as well as clinicians in an effort to improve access to care and close gaps in knowledge within communities.